SLC7A11(Solute Carrier Family 7 Member 11，又名xCT)是溶质转运第7家族的第11个成员，属于胱氨酸/谷氨酸逆向转运蛋白，主要参与氨基酸在质膜上的转运，来保护细胞免受氧化应激的损伤，维持细胞氧化还原平衡，从而阻止细胞因脂质过氧化而导致的细胞死亡 [1-3]。

  SLC7A11蛋白在多种恶性肿瘤中过表达，已经被证实与胶质瘤、乳腺癌、卵巢癌、肝癌和肺癌等实体恶性肿瘤的生长、预后、转移和治疗密切相关，为恶性肿瘤新的潜在分子标志物和治疗靶点[4-5]。然而，目前 SLC7A11 抑制剂的临床应用受限，急需进一步研究高特异性 SLC7A11 抑制剂用于恶性肿瘤的治疗。此外，SLC7A11蛋白在血液系统恶性肿瘤中的临床意义及机制有待于进一步研究，此类研究可能为相关疾病提供潜在的治疗靶点，并为临床相关分子标志物提供理论基础及参考。

  [1] Bassi, Maria, et al. "Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc-." Pflügers Archiv 442.2 (2001): 286-296.

  [2] Lin, Wenyu, et al. "SLC7A11/xCT in cancer: biological functions and therapeutic implications." American journal of cancer research 10.10 (2020): 3106.

  [3] Koppula, Pranavi, et al. "Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer." Cancer Communications 38.1 (2018): 1-13.

  [4] Gout PW, Kang YJ, Buckley DJ, et al. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells[J]. Leukemia, 1997, 11(8):1329-1337.

  [5] Gout PW, Buckley AR, Simms CR, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc - cystine transporter: a new action for an old drug[J]. Leukemia, 2001, 15(10):1633- 1640.